Long-Term NHL Survivors with Comorbidity, Symptom Burden, Need Supportive Services

Share this content:

(ChemotherapyAdvisor) – The presence of comorbidity or symptom burden in long-term survivors of non-Hodgkin lymphoma (NHL) “should alert the clinician to a potential need for supportive services,” a study reported in the Journal of Clinical Oncology online December 3.

This is especially important for patients whose quality of life (QOL) steadily deteriorates over time, yet who no longer receive health care from an oncology or survivorship clinic, noted Sophia K. Smith, PhD, of Duke Cancer Institute, Duke University Medical Center, Durham, NC, and colleagues. “Consequently, they may lack much-needed support at later stages of survivorship when they have become invisible to the system of care.”

Advances in the treatment of NHL have led to improved survival; consequently, more than 500,000 individuals in the United States are living with a history of NHL. “However, NHL survivors are an understudied group,” Dr. Smith noted. “Little is known about the longitudinal effects of recurrence and/or systemic treatment on QOL-related outcomes such as health and functioning.”

The investigators mailed surveys to 682 NHL survivors who had participated in a study 5 years earlier; 566 (83%) participated in the current survey. Mean years postdiagnosis was 15.3; 52% were women, and 87% were white.

“One third of participants (32%) reported persistently high or improved QOL, yet a notable proportion (42%) reported persistently low or worsening QOL since the earlier survey,” the investigators found.

Independent predictors of poor QOL were older age, more comorbidity, and more or increasing negative and decreasing positive perceptions of cancer's impact; the latter was related to lymphoma symptom burden, less social support, and having received transplantation.

An improvement in physical health was noted by those who received only biologic systemic therapy.

“Our results show that QOL and the cancer experience, and their changes over time, are complex. Although we can signal specific subpopulations at risk, there isn't a one-size-fits-all approach; it is difficult to predict the long-term outcome for any particular person,” they reported.

These results suggest patient-reported monitoring should be integrated as a standard of survivorship care.

Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs